Inhalable IL-10 as an Aerosolized Therapeutic Approach to Acute Lung Injury in Mice

Background: Acute lung injury (ALI) is a severe inflammatory condition with substantial morbidity and mortality, with no approved pharmacologic therapies targeting its underlying inflammatory pathways. Prior studies demonstrated that intratracheal interleukin (IL)−10 reduces lipopolysaccharide (LPS)- and organic dust-induced lung and systemic inflammation. Methods: The present study evaluated the aerosol performance and efficacy of nebulized IL-10 against a high-dose LPS-induced ALI model with comparisons to shock-dose dexamethasone (5 mg/kg, intraperitoneal injections). C57BL/6 male mice were challenged with LPS (5 mg/mL) and treated with low- (0.1 mg/mL), mid- (0.5 mg/mL), or high-dose (1 mg/mL) IL-10, or vehicle, all by nose-only aerosol inhalation (15-minute exposure duration), with euthanasia on day 2. Results: Aerosolized IL-10 exhibited a mass median aerodynamic diameter of 1.66 µm (geometric standard deviation 2.04). Pulmonary deposited doses were 5.5–5.7 µg/mouse for LPS and 10.4, 21.3, and 38.4 (ug/kg) for low-, mid-, and high-dose IL-10. LPS-induced weight loss (18.6%) was reduced by high IL-10 (8.4%) and dexamethasone (7.0%), with no significant difference between treatments. Increased lung weights (40.8%) following LPS challenge were significantly reduced by mid- and high-dose IL-10 and dexamethasone. LPS-induced airway total cell and neutrophil counts in bronchoalveolar lavage fluid were not reduced by either treatment. In contrast, IL-10 treatment produced dose-dependent reductions in LPS-induced pro-inflammatory mediators (TNF-α, IL-1β, IL-6, IL-12p70, IFN-γ, KC/CXCL1, MCP-1, and MIP-1α), with beneficial responses at the high IL-10 dose comparable to dexamethasone. Histopathology demonstrated dose-responsive reductions in LPS-induced peribronchovascular mixed cellular lung inflammation, significant at mid- and high IL-10 doses and comparable to dexamethasone. Conclusion: Overall, aerosolized IL-10 demonstrated aerodynamic properties consistent with deep lung penetration and dose-dependent efficacy at ≥21.3 µg/kg, achieving anti-inflammatory effects comparable with dexamethasone in this ALI murine model.

Authors

Institutions

Publication Details

Journal
Journal of Aerosol Medicine and Pulmonary Drug Delivery
Published
2026-11-17
DOI
https://doi.org/10.1177/19412711261507383
Primary Topic
Inhalation and Respiratory Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Inhalable IL-10 as an Aerosolized Therapeutic Approach to Acute Lung Injury in Mice

Samuel A. Vance, Todd A. Wyatt, Jill A. Poole, Jason M. Cox et al.
Journal of Aerosol Medicine and Pulmonary Drug Delivery
Inhalation and Respiratory Drug Delivery
article

Inhalable IL-10 as an Aerosolized Therapeutic Approach to Acute Lung Injury in Mice

Samuel A. Vance, Todd A. Wyatt, Jill A. Poole, Jason M. Cox, Steven M. Dudek, Edward G. Barrett, Amy J. Nelson
article en

Abstract

Background: Acute lung injury (ALI) is a severe inflammatory condition with substantial morbidity and mortality, with no approved pharmacologic therapies targeting its underlying inflammatory pathways. Prior studies demonstrated that intratracheal interleukin (IL)−10 reduces lipopolysaccharide (LPS)- and organic dust-induced lung and systemic inflammation. Methods: The present study evaluated the aerosol performance and efficacy of nebulized IL-10 against a high-dose LPS-induced ALI model with comparisons to shock-dose dexamethasone (5 mg/kg, intraperitoneal injections). C57BL/6 male mice were challenged with LPS (5 mg/mL) and treated with low- (0.1 mg/mL), mid- (0.5 mg/mL), or high-dose (1 mg/mL) IL-10, or vehicle, all by nose-only aerosol inhalation (15-minute exposure duration), with euthanasia on day 2. Results: Aerosolized IL-10 exhibited a mass median aerodynamic diameter of 1.66 µm (geometric standard deviation 2.04). Pulmonary deposited doses were 5.5–5.7 µg/mouse for LPS and 10.4, 21.3, and 38.4 (ug/kg) for low-, mid-, and high-dose IL-10. LPS-induced weight loss (18.6%) was reduced by high IL-10 (8.4%) and dexamethasone (7.0%), with no significant difference between treatments. Increased lung weights (40.8%) following LPS challenge were significantly reduced by mid- and high-dose IL-10 and dexamethasone. LPS-induced airway total cell and neutrophil counts in bronchoalveolar lavage fluid were not reduced by either treatment. In contrast, IL-10 treatment produced dose-dependent reductions in LPS-induced pro-inflammatory mediators (TNF-α, IL-1β, IL-6, IL-12p70, IFN-γ, KC/CXCL1, MCP-1, and MIP-1α), with beneficial responses at the high IL-10 dose comparable to dexamethasone. Histopathology demonstrated dose-responsive reductions in LPS-induced peribronchovascular mixed cellular lung inflammation, significant at mid- and high IL-10 doses and comparable to dexamethasone. Conclusion: Overall, aerosolized IL-10 demonstrated aerodynamic properties consistent with deep lung penetration and dose-dependent efficacy at ≥21.3 µg/kg, achieving anti-inflammatory effects comparable with dexamethasone in this ALI murine model.

Journal of Aerosol Medicine and Pulmonary Drug Delivery
University of Illinois Chicago (US), University of Chicago (US), VA Nebraska Western Iowa Health Care System (US), University of Nebraska Medical Center (US)
Inhalation and Respiratory Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon